McGill.CA / Cystic Fibrosis Transmembrane Regulator Function Laboratory

On this page:

Full publication list (PubMed)

 

Recent publications 

 

*Klassen MC, Balázs A, Zöllner J, Cleve N, Czichon L, von Schledorn L, Hegermann J, Nawroth JC, Roth D, Mielenz M, Hedtfeld S, Stanke F, Rubil T, Ius F, Jonigk D, Hanrahan JW, Ruhparwar A, Olmer R, Mall MA, Merkert S, Martin U. (2025). Human induced pluripotent stem cells for in vitro modeling of impaired mucociliary clearance in cystic fibrosis lung disease. Stem Cell Res Ther. 16(1):573. 

*Ponomarchuk O, Boudreault F, Gryczynski I, Lee B, Dzyuba SV, Fudala R, Gryczynski Z, Hanrahan JW, Grygorczyk R. (2025). Nanoscale Viscometry Reveals an Inherent Mucus Defect in Cystic Fibrosis. ACS Nano. 19(4): 4637-4649.

*Singh N, Cunnington RH, Bhagirath A, Vaishampayan A, Khan MW, Gupte T, Duan K, Gounni AS, Dakshisnamurti S, Hanrahan JW, Chelikani P. (2024). Bitter taste receptor T2R14-Gai coupling mediates innate immune responses to microbial quorum sensing molecules in cystic fibrosis. iScience. 27(12): 111286.

*Yousefi Adlsadabad S, Hanrahan JW, Kakkar A. (2024). mRNA Delivery: Challenges and Advances through Polymeric Soft Nanoparticles. Int J Mol Sci. 25(3):1739.

*Ondra M, Lenart L, Centorame A, Dumut DC, He A, Zaidi SSZ, Hanrahan JW, De Sanctis JB, Radzioch D, Hajduch M. (2023). CRISPR/Cas9 bioluminescence-based assay for monitoring CFTR trafficking to the plasma membrane. Life Sci Alliance. 7(1): e202302045.

*Sato Y, Kim D, Turner MJ, Luo Y, Zaidi SSZ, Thomas DY, Hanrahan JW. (2023). Ionocyte-specific regulation of Cystic Fibrosis Transmembrane Regulator. Am J Respir Cell Mol Biol. 69(3): 281-294.

*Hanrahan JW, Abu-Arish A, Wong FH, Turner MJ, Carlile GW, Thomas DY, Cantin AM. (2022). Chronic obstructive pulmonary disease and the modulation of CFTR by acute exposure to cigarette smoke.  Am. J. Physiol - Cell Physiol. 323(5): C1374-C1392.

*Stevers LM, Wolter M, Carlile GW, Macdonald D, Richard L, Gielkens F, Hanrahan JW, Thomas DY, Chakka SK, Peterson ML, Thomas H, Brunsveld L, Ottmann C. (2022). Macrocycle-stabilization of its interaction with 14-3-3 increases plasma membrane localization and activity of CFTR.  Nature Communications. 13(1):3586.

*Centorame A, Dumut DC, Youssef M, Ondra M, Kianicka I, Shah J, Paun RA, Ozdian T, Hanrahan JW, Gusev E, Petrof B, Hajduch M, Pislariu R, De Sanctis JB, Radzioch D. (2022). Treatment with LAU-7b complements CFTR modulator therapy by improving lung physiology and normalizing lipid imbalance associated with CF lung disease. Front. Pharmacol.13: 1-18.

*Carlile GW, Yang Q, Matthes E, Liao J, Birault V, Sneddon HF, Poole DL, Hall CJ, Hanrahan JW, Thomas DY. (2022). The NSAID glafenine rescues class 2 CFTR mutants via cyclooxygenase 2 inhibition of the arachidonic acid pathway. Sci Report. 12(1): 4595-4614.

*Abu-Arish A, Pandzíc E, Luo Y, Sato Y, Turner MJ, Wisem PW, Hanrahan JW. (2022). Lipid-driven CFTR clustering is impaired in CF and restored by corrector drugs. Journal of Cell Science. 135(5): 1-13.

*Lopes-Pacheco M, Bacalhau M, Ramalho SS, Silva IAL, Ferreira FC, Carlile GW, Thomas DY, Farinha CM, Hanrahan JW, Amaral MD. (2022). Rescue of Mutant CFTR Trafficking Defect by the Investigational Compound MCG1516A. Cells. 11(1): 136-158.

*Turner MJ, Sato Y, Thomas DY, Abbott-Banner K, Hanrahan JW. (2021). Phosphodiesterase 8A Regulates CFTR Activity in Airway Epithelial Cells. Cellular Physiology and Biochemistry. 55: 784-804.

*Sato Y, Mustafina KR, Luo Y, Martini C, Thomas DY, Wiseman PW, Hanrahan JW. (2021). Nonspecific binding of common anti-CFTR antibodies in ciliated cells of human airway epithelium. Scientific Reports. 11(1): 23256-23271.

*Turner MJ, Abbott-Banner K, Thomas DY, Hanrahan JW. (2021). Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis. Pharmacology and Therapeutics. 224: 1-14.

*Kim D, Liao J, Scales N, Martini C, Luan X, AbuArish A, Robert R, Luo Y, McKay GA, Nguyen D, Tewfik MA, Poirier CD, Matouk E, Ianowski JP, Frenkiel S, Hanrahan JW. (2021). Large pH oscillations promote host defense against human airways infection. J Exp Med. 218(4): 1-15.

*Kouthouridis S, Goepp J, Martini C, Matthes E, Hanrahan JW, Moraes C. (2021). Oxygenation as a driving factor in epithelial differentiation at the air-liquid interface. Integrative Biology. 13(3): 61-72.

*Veltman M, De Sanctis JB, Stolarczyk M, Klymiuk N, Bähr A, Brouwer RWW, Oole E, Shah J, Ozdian T, Liao J, Martini, Radzioch D, Hanrahan JW, Scholte BJ. (2021). CFTR correctors and antioxidants partially normalize lipid imbalance butnot abnormal basal inflammatory cytokine profile in CF bronchial epithelial cells. Frontiers in Physiology. 12: 1-18.

*Turner MJ, Dauletbaev N, Lands LC, Hanrahan JW. (2020). The phosphodiesterase inhibitor ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4. J Pharmacol Exp Ther. 375(3): 414-429.

*Lopes-Pacheco M, Silva IAL, Turner MJ, Carlile GW, Sondo E, Thomas DY, Pedemonte N, Hanrahan JW, Amaral MD. (2020). Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR. Biochem Pharmacol. 180: 1-11.

*Turner MJ, Luo Y, Thomas DT, Hanrahan JW. (2020). The dual phosphodiesterase 3/4 inhibitor RPL554 stimulates rare class III and IV CFTR mutants. Am. J. Physiol. - Lung Cell and Mol. Physiol.318(5): L908- L920.

*Garíc D, De Sanctis JB, Dumut DC, Shah J, Peña MJ, Youssef M, Petrof BJ, Kopriva F, Hanrahan JW, Hajduch M, Radzioch D. (2020). Fenretinide favorably affects mucins (MUC5AC/MUC5B) and fatty acid imbalance in a manner mimicking CFTR-induced correction. Biochim Biophys Acta - Mol Cell Biol Lipids. 1865(2): 158538.

 

Reviews

*Hanrahan JW, Matthes E, Carlile G, Thomas DY 2017. Corrector combination therapies for F508del-CFTR. Curr Opin Pharmacol. 34:105-111.

*Frizzell, RA & Hanrahan, JW 2012. Physiology of epithelial chloride and fluid secretion. In Cystic Fibrosis: Molecular Basis, Physiological Changes, and Therapeutic strategies," ed. JR Riordan, RC Boucher, and PM Quinton, Cold Spring Harbor Perspect Med 2:a009563

 



While this web page is accessible worldwide, McGill University is on land which has served and continues to serve as a site of meeting and exchange amongst Indigenous peoples, including the Haudenosaunee and Anishinabeg nations. We acknowledge and thank the diverse Indigenous peoples whose footsteps mark this territory on which peoples of the world now gather. This land acknowledgement is shared as a starting point to provide context for further learning and action.

Back to top